Kristie Ann Vanpatten

US Patent:

20100209928, Aug 19, 2010

Filed:

Oct 16, 2008

Appl. No.:

12/682310

Inventors:

Mana Mirza - Jazan, SA
Elizabeth Shaughnessy - Cincinnati OH, US
Georg F. Weber - Cincinnati OH, US
John K. Hurley - Tucson AZ, US
Kristie A. Vanpatten - Oro Valley AZ, US
Gary Pestano - Oro Valley AZ, US

International Classification:

C12Q 1/68
C12Q 1/02
G01N 33/53

US Classification:

435 6, 435 29, 435 71

Abstract:

The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).

US Patent:

20070031902, Feb 8, 2007

Filed:

Aug 3, 2006

Appl. No.:

11/462356

Inventors:

Gary Pestano - Oro Valley AZ, US
Linda Samadzadeh - Tacoma WA, US
Kristie Vanpatten - Oro Valley AZ, US

International Classification:

G01N 33/574

US Classification:

435007230

Abstract:

This invention provides methods and reagents for determining or predicting response to cancer therapy, as well as dual therapy treatments.

US Patent:

20180119232, May 3, 2018

Filed:

Dec 13, 2017

Appl. No.:

15/840611

Inventors:

- Tucson AZ, US
- Cincinnati OH, US
John K. Hurley - Tucson AZ, US
Kristie A. Vanpatten - Oro Valley AZ, US
Gary Pestano - Oro Valley AZ, US
Georg F. Weber - Cincinnati OH, US

International Classification:

C12Q 1/6886
A61K 47/68

Abstract:

The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).